Savara Inc (NASDAQ:SVRA) Given Consensus Recommendation of “Buy” by Analysts

Shares of Savara Inc (NASDAQ:SVRA) have earned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $11.17.

SVRA has been the subject of several recent analyst reports. Guggenheim boosted their price objective on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research note on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Savara in a research note on Wednesday, August 14th. Finally, Oppenheimer boosted their price objective on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, June 26th.

Hedge Funds Weigh In On Savara

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its stake in shares of Savara by 41.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after purchasing an additional 746,407 shares in the last quarter. Wellington Management Group LLP bought a new stake in Savara during the 4th quarter valued at $9,683,000. Vanguard Group Inc. raised its holdings in Savara by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after buying an additional 148,673 shares during the last quarter. Swiss National Bank bought a new stake in Savara during the 1st quarter valued at $732,000. Finally, Superstring Capital Management LP bought a new stake in Savara during the 4th quarter valued at $3,827,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Stock Performance

NASDAQ SVRA opened at $4.24 on Monday. The company’s 50 day moving average is $4.34 and its 200-day moving average is $4.47. Savara has a 12-month low of $3.12 and a 12-month high of $5.70. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $585.92 million, a P/E ratio of -11.46 and a beta of 0.97.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Sell-side analysts predict that Savara will post -0.44 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.